Ask AI
ASCO 2024 Lymphoma and Leukemia

CE / CME

Bridging Lymphoma and Leukemia Discoveries to Practice

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: July 01, 2025

Expiration: December 31, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

The randomized phase III ASC4START trial investigated asciminib vs nilotinib for patients aged 18 years or older with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Asciminib was superior to nilotinib in which of the following patient populations with respect to the primary endpoint of time to study treatment discontinuation due to adverse event (TTDAE)?